Reposted by @eileend6.bsky.social
NEW: in court-ordered update on the status of a bogus FDA “review” of the abortion drug mifepristone, DOJ says data coming in December with review complete “not later than March 2027.” Footnote says they could restrict access as data comes in 👀
litigationtracker.law.georgetown.edu/wp-content/u...
![Case 6:25-cv-01491-DCJ-DJA Document 278
Filed 10/07/26
9172
Page 1 of 5 PagelD #:
IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA
LAFAYETTE DIVISION
THE STATE OF LOUISIANA, et al.,
Plaintiffs,
V.
U.S. FOOD AND DRUG ADMINISTRATION, et al.,
No. 6:25-cv-01491-DCJ-DJA
Federal Defendants,
and
DANCO LABORATORIES, et al.,
Intervenor Defendants.
FEDERAL DEFENDANTS' STATUS REPORT
On April 7, 2026, this Court denied Plaintiffs' motion for preliminary relief and
granted Federal Defendants' motion to stay proceedings "pending completion of [the
U.S. Food and Drug Administration's] ongoing review of the mifepristone REMS and
issuance of any resulting agency decision." ECF No. 258 at 36. The Court directed FDA to file a report within six months "providing the Court with the status of its review in
terms of process and any updated timeframe for completion of the review." Id.
Accordingly, FDA reports as follows:
FDA is conducting a study to assess the safety of mifepristone, in a
regimen with misoprostol, for the medical termination of intrauterine pregnancy](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:4fdfjfnhhyeo4hsmoxpeazsg/bafkreiffxirdndcr24dlnxd5aaiakptfje2lbwcknxicqiwddxxmxfr32y)
